Monoclonal Antibodies: A Brief Review on Delivery Trends
Abstract
Immunoglobulin derivatives which are derived from the monoclonal cell line and which offers a wide range of specificity are the monoclonal antibodies. They are specially produced by the hybridoma technology by the fusion of B-cells with the immortal myeloma cells in presence of PEG. Humanized mAbs are considered to be the fastest growing group in clinical trials. After development, these mAbs undergoes analytical evaluation for their efficient characterization. Developed hybridomas can be preserved for long term use through the cryopreservation techniques. Monoclonal antibodies can be delivered for the therapeutic purpose through the various systemic and non-systemic routes. Large groups of the antibodies are found to be very effective through the oral routes and the ophthalmic routes. Besides the therapeutic application for the treatment of various infectious and autoimmune diseases, these groups of therapeutics show different limitations. Monoclonal antibodies after development suffers from the stability issues and using the various techniques, the stability can be increased. With the advancement of science and technology, we can observe various advances in the monoclonal antibody development like brain targeting is possible through the antibody engineering techniques. Variability and control challenges in the serum based acquisitions, consumption of time, difficulty in the development, potential limitation in the sequence and epitope diversity etc. are some of the challenges associated with the monoclonal antibodies.
Keywords: Immunoglobulin, Hybridoma Technology, Cryopreservation, Antibody Engineering
Keywords:
Immunoglobulin, Hybridoma Technology, Cryopreservation, Antibody EngineeringDOI
https://doi.org/10.22270/jddt.v15i2.6992References
1. Goli N, Bolla PK, Talla V. Antibody-drug conjugates (ADCs): Potent biopharmaceuticals to target solid and hematological cancers-an overview. Journal of Drug Delivery Science and Technology. 2018;48:106-17. https://doi.org/10.1016/j.jddst.2018.08.022
2. Liu JK. The history of monoclonal antibody development-progress, remaining challenges and future innovations. Annals of medicine and surgery. 2014;3(4):113-6. https://doi.org/10.1016/j.amsu.2014.09.001 PMid:25568796 PMCid:PMC4284445
3. Berger M, Shankar V, Vafai A. Therapeutic applications of monoclonal antibodies. The American journal of the medical sciences. 2002;324(1):14-30. https://doi.org/10.1097/00000441-200207000-00004 PMid:12120821 PMCid:PMC7093874
4. Beck A, Wagner-Rousset E, Bussat M-C, Lokteff M, Klinguer-Hamour C, Haeuw J-F, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Current pharmaceutical biotechnology. 2008;9(6):482-501. https://doi.org/10.2174/138920108786786411 PMid:19075687
5. Ferri N, Bellosta S, Baldessin L, Boccia D, Racagni G, Corsini A. Pharmacokinetics interactions of monoclonal antibodies. Pharmacological research. 2016;111:592-9. https://doi.org/10.1016/j.phrs.2016.07.015 PMid:27438459
6. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clinical pharmacokinetics. 2010;49:493-507. https://doi.org/10.2165/11531280-000000000-00000 PMid:20608753
7. Shimizu M, Miwa Y, Hashimoto K, Goto A. Encapsulation of chicken egg yolk immunoglobulin G (IgY) by liposomes. Bioscience, biotechnology, and biochemistry. 1993;57(9):1445-9. https://doi.org/10.1271/bbb.57.1445 PMid:7764217
8. Shimizu M, Fitzsimmons Rc, NAKAI S. Anti‐E. coli lmmunoglobulin Y isolated from egg yolk of immunized chickens as a potential food ingredient. Journal of Food Science. 1988;53(5):1360-8. https://doi.org/10.1111/j.1365-2621.1988.tb09277.x
9. Aalilouch K, Berbri I. Monoclonal Antibody Production Using Hybridoma Technology: Advances, Challenges and Applications. Int J Vet Med. 2024;3(2):1-4.
10. Mitra S, Tomar PC. Hybridoma technology; advancements, clinical significance, and future aspects. Journal of Genetic Engineering and Biotechnology. 2021;19:1-12. https://doi.org/10.1186/s43141-021-00264-6 PMid:34661773 PMCid:PMC8521504
11. Fekete S, Gassner A-L, Rudaz S, Schappler J, Guillarme D. Analytical strategies for the characterization of therapeutic monoclonal antibodies. TrAC Trends in Analytical Chemistry. 2013;42:74-83. https://doi.org/10.1016/j.trac.2012.09.012
12. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. nature. 1975;256(5517):495-7. https://doi.org/10.1038/256495a0 PMid:1172191
13. Tyagi S, Sharma P, Kumar N, Visht S. Hybridoma technique in pharmaceutical science. International Journal of Pharm Tech Research. 2011;3(1):459-63.
14. Chen Y, Wang W, Yuan H, Li Y, Lv Z, Cui Y, et al. Current state of monoclonal antibody therapy for allergic diseases. Engineering. 2021;7(11):1552-6. https://doi.org/10.1016/j.eng.2020.06.029
15. Chang TW, Shiung Y-Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. Journal of Allergy and Clinical Immunology. 2006;117(6):1203-12. https://doi.org/10.1016/j.jaci.2006.04.005 PMid:16750976
16. Craig T, Magerl M, Levy DS, Reshef A, Lumry WR, Martinez-Saguer I, et al. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2022;399(10328):945-55. https://doi.org/10.1016/S0140-6736(21)02225-X PMid:35219377
17. Edwards P. Some properties and applications of monoclonal antibodies. Biochemical Journal. 1981;200(1):1. https://doi.org/10.1042/bj2000001 PMid:7036988 PMCid:PMC1163495
18. Ling N. Properties of the monoclonal antibodies produced by hybridoma technology and their application to the study of diseases. Immunology. 1983;49(1):202.
19. Guilleminault L, Michelet M, Reber LL. Combining anti-IgE monoclonal antibodies and oral immunotherapy for the treatment of food allergy. Clinical Reviews in Allergy & Immunology. 2022;62(1):216-31. https://doi.org/10.1007/s12016-021-08902-0 PMid:34550555
20. Prašnikar M, Žiberna MB, Matjaž MG, Grabnar PA. Novel strategies in systemic and local administration of therapeutic monoclonal antibodies. International journal of pharmaceutics. 2024:124877. https://doi.org/10.1016/j.ijpharm.2024.124877 PMid:39490550
21. Hwang SR, Byun Y. Advances in oral macromolecular drug delivery. Expert opinion on drug delivery. 2014;11(12):1955-67. https://doi.org/10.1517/17425247.2014.945420 PMid:25078141
22. Batens M, Massant J, Teodorescu B, Van den Mooter G. Formulating monoclonal antibodies as powders for reconstitution at high concentration using spray drying: Models and pitfalls. European Journal of Pharmaceutics and Biopharmaceutics. 2018;127:407-22. https://doi.org/10.1016/j.ejpb.2018.02.002 PMid:29499299
23. Ishikawa H, Ochi H, Chen M-L, Frenkel D, Maron R, Weiner HL. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 2007;56(8):2103-9. https://doi.org/10.2337/db06-1632 PMid:17456848
24. Miller MK, Chapa-Villarreal FA, Oldenkamp HF, Elder MG, Venkataraman AK, Peppas NA. Stimuli-responsive self-assembled polymer nanoparticles for the oral delivery of antibodies. Journal of Controlled Release. 2023;361:246-59. https://doi.org/10.1016/j.jconrel.2023.07.044 PMid:37524149
25. Petersson M, Thrane SW, Gram L, Muyldermans S, Laustsen AH. Orally delivered single-domain antibodies against gastrointestinal pathogens. Trends in Biotechnology. 2023;41(7):875-86. https://doi.org/10.1016/j.tibtech.2023.01.015 PMid:36774206
26. Challacombe S, Rahman D, Jeffery H, Davis S, O'Hagan D. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen. Immunology. 1992;76(1):164.
27. Rodrigues EB, Farah ME, Maia M, Penha FM, Regatieri C, Melo GB, et al. Therapeutic monoclonal antibodies in ophthalmology. Progress in retinal and eye research. 2009;28(2):117-44. https://doi.org/10.1016/j.preteyeres.2008.11.005 PMid:19114125
28. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nature reviews Drug discovery. 2010;9(4):325-38. https://doi.org/10.1038/nrd3003 PMid:20305665
29. Wurch T, Pierré A, Depil S. Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. Trends in biotechnology. 2012;30(11):575-82. https://doi.org/10.1016/j.tibtech.2012.07.006 PMid:22944617
30. Ma H, Ó'Fágáin C, O'Kennedy R. Antibody stability: A key to performance-Analysis, influences and improvement. Biochimie. 2020;177:213-25. https://doi.org/10.1016/j.biochi.2020.08.019 PMid:32891698
31. Awwad S, Angkawinitwong U. Overview of antibody drug delivery. Pharmaceutics. 2018;10(3):83. https://doi.org/10.3390/pharmaceutics10030083 PMid:29973504 PMCid:PMC6161251
32. Gu G, Fang M. [Advances of monoclonal antibodies and analysis of marketed antibody drugs]. Sheng wu gong cheng xue bao = Chinese journal of biotechnology. 2024;40(5):1431-47.
33. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature reviews drug discovery. 2010;9(10):767-74. https://doi.org/10.1038/nrd3229 PMid:20811384
34. Jones PT, Dear PH, Foote J, Neuberger MS, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature. 1986;321(6069):522-5. https://doi.org/10.1038/321522a0 PMid:3713831
35. Sela M, Poley M, Mora‐Raimundo P, Kagan S, Avital A, Kaduri M, et al. Brain‐targeted liposomes loaded with monoclonal antibodies reduce alpha‐synuclein aggregation and improve behavioral symptoms in Parkinson's disease. Advanced Materials. 2023;35(51):2304654. https://doi.org/10.1002/adma.202304654 PMid:37753928 PMCid:PMC7615408
Published
Abstract Display: 73 
PDF Downloads: 66 PDF Downloads: 4 How to Cite
Issue
Section
Copyright (c) 2025 Diwas Adhikari , Sharada Pokhrel
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.